LTR Pharma Limited Doses First Patients in SPONTAN® Phase II Clinical Study
LTR Pharma Limited (ASX: LTP) has announced the successful dosing of the first patients in its Phase II pharmacokinetic clinical study for SPONTAN®, a rapid-acting intranasal spray designed to treat erectile dysfunction. This marks a key milestone in the study, transitioning from recruitment to active data generation. The study will assess both single- and multiple-dose pharmacokinetics in 27 healthy male participants, with a focus on those aged 65 years or older, in line with FDA guidance for geriatric-use assessments.
The data generated from this study will play a crucial role in informing future prescribing information, particularly for older patients who may require dose adjustments with oral erectile dysfunction therapies. Initial data is expected in Q2 CY2026 and will be pivotal in advancing SPONTAN®’s U.S. regulatory submission. This milestone represents an important step in LTR Pharma’s broader commercial strategy.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
LTR Pharma Limited Doses First Patients in SPONTAN® Phase II Clinical Study
LTR Pharma Limited (ASX: LTP) has announced the successful dosing of the first patients in its Phase II pharmacokinetic clinical study for SPONTAN®, a rapid-acting intranasal spray designed to treat erectile dysfunction. This marks a key milestone in the study, transitioning from recruitment to active data generation. The study will assess both single- and multiple-dose pharmacokinetics in 27 healthy male participants, with a focus on those aged 65 years or older, in line with FDA guidance for geriatric-use assessments.
The data generated from this study will play a crucial role in informing future prescribing information, particularly for older patients who may require dose adjustments with oral erectile dysfunction therapies. Initial data is expected in Q2 CY2026 and will be pivotal in advancing SPONTAN®’s U.S. regulatory submission. This milestone represents an important step in LTR Pharma’s broader commercial strategy.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au